IMU’s discovery engine maps the immune system in unprecedented detail and scale to deliver unique, systems-level immune insights.
Use our platform today to measure +2,000 discrete cell subset capturing systems-level immune profiles, to power in-depth disease modeling, drug development, patient monitoring, and translational research
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
London, UK, 24 January 2024 — IMU Biosciences (or “the Company”), a techbio company revolutionising immune powered precision medicine, today announces the close of a £11.5 million Series A financing round. The round was led by European tech VC Molten Ventures and included LifeX Ventures and other individuals.
